课题基金 / 基金详情

Childhood Asthma in Urban Settings Clinical Research Network - Leadership Center

Childhood Asthma in Urban Settings Clinical Research Network - Leadership Center
城市环境中的儿童哮喘临床研究网络 - 领导中心
批准号:
10391566
负责人:
James E. Gern
金额:
$665.07万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-04-12 至 2028-03-31

项目摘要

项目成果

James E. Gern的其他基金

相关文献

中文摘要
翻译
项目概要/摘要 我们的城市儿童哮喘(原因)-领导中心提案的总体目标是 提供行政领导和支持,以发展和开展合作研究,以解决高 城市社区儿童哮喘的优先未满足需求,包括:a)制定预防战略, 哮喘,B)改善治疗并抑制进展,c)减少严重恶化,和d)定义 呼吸系统健康和疾病的内在型。提出了四个假设来实现这些目标。第一、 在婴儿期补充免疫调节细菌将防止肠道中的早期生命扰动 与过敏性致敏和哮喘发生风险相关的微生物组,以及 会促进气道黏膜免疫发育。其次,鉴于蟑螂(CR)过敏的重要性, 和暴露于城市儿童哮喘发病率,CR免疫治疗将改善哮喘控制, 减少疾病进展。第三,我们提出气道细胞的转录分析将定义T2-低 这些研究有助于阐明非特应性和特应性哮喘的发病机制,并为治疗提供新的见解。 最后,在严重急性发作期间获得的气道细胞和分泌物的多组学评估导致 艾德就诊和住院将揭示新的机制途径,以告知改善治疗, 预防我们提出了五个协议来测试这些假设: 1.城市环境与儿童哮喘研究(URECA) 2.微生物补充剂(STMC-103 H)对微生物定植和免疫发育的影响 3.蟑螂(CR)免疫治疗(IT)在城市中重度哮喘儿童中的应用 Omalizumab 4.低T2(非特应性)哮喘的发病机制 5.急诊科(艾德)和医院中的重度哮喘急性发作: 预防和治疗 我们希望我们提出的CAUSE研究计划将提供所需的关键信息, 认识城市儿童的哮喘表型和内在型,改善哮喘治疗, 预防的方向。总体而言,这些研究将继续采用联合国的严格方案办法, NIAID哮喘网络致力于实现疾病改善和预防的长期目标, 城市社区低收入家庭高危儿童的疾病。
英文摘要
PROJECT SUMMARY/ABSTRACT The overall goals of our Childhood Asthma in Urban Settings (CAUSE)-Leadership Center proposal are to provide administrative leadership and support to develop and conduct collaborative research to address high priority unmet needs for childhood asthma in urban communities, including: a) developing strategies to prevent asthma, b) improving treatment and inhibiting progression, c) reducing severe exacerbations, and d) defining endotypes of respiratory health and disease. Four hypotheses are proposed to accomplish these goals. First, supplementation with immune modulating bacteria in infancy will prevent the early life perturbations in the gut microbiome that have been associated with risk for the development of allergic sensitization and asthma, and will promote airway mucosal immune development. Second, given the importance of cockroach (CR) allergy and exposure to asthma morbidity in urban children, CR immunotherapy will improve asthma control and reduce disease progression. Third, we propose that transcriptional analysis of airway cells will define T2-low mechanisms that contribute to both non-atopic and atopic asthma and provide new insights into treatment. Finally, multi-omics evaluation of airway cells and secretions obtained during severe exacerbations leading to ED visits and hospitalizations will reveal novel mechanistic pathways to inform improved treatment and prevention. We propose five protocols to test these hypotheses: 1. Urban Environment and Childhood Asthma study (URECA) 2. Effects of a Microbial Supplement (STMC-103H) on Microbial Colonization and Immune Development 3. Cockroach (CR) Immunotherapy (IT) in Urban Children with Moderate-Severe Asthma Protected by Omalizumab 4. Pathogenesis and Mechanisms of T2-low (Non-Atopic) Asthma 5. Severe Asthma Exacerbations in the Emergency Department (ED) and Hospital: Identifying Targets for Prevention and Treatment It is our expectation that our proposed CAUSE research program will provide critical information needed to recognize asthma phenotypes and endotypes in urban children, improve treatment of asthma and establish direction for prevention. Collectively, these studies will continue the rigorous programmatic approach of the NIAID Asthma Networks towards achieving the long-term goals of disease modification and prevention of disease in high-risk children of low-income families living in urban communities.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Childhood Asthma in Urban Settings Clinical Research Network - Leadership Center
  • 批准号:
    10209602
  • 项目类别:
  • 资助金额:
    $695.27万
  • 财政年份:
    2021
  • 负责人:
    James E. Gern
  • 依托单位:
Childhood Asthma in Urban Settings Clinical Research Network - Leadership Center
  • 批准号:
    10608089
  • 项目类别:
  • 资助金额:
    $676.71万
  • 财政年份:
    2021
  • 负责人:
    James E. Gern
  • 依托单位:
Identifying Coronavirus B-cell Epitopes Associated with COVID-19 Illness Severity
  • 批准号:
    10170660
  • 项目类别:
  • 资助金额:
    $40.6万
  • 财政年份:
    2020
  • 负责人:
    James E. Gern
  • 依托单位:
Human epidemiology and response to SARS-CoV-2 (HEROS)
  • 批准号:
    10230381
  • 项目类别:
  • 资助金额:
    $40.31万
  • 财政年份:
    2020
  • 负责人:
    James E. Gern
  • 依托单位: